Yunnan Cancer Hospital,The Third Affiliated Hospital of Kunming Medical University ,Yunnan Cancer Center
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Huang, Yunchao
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
450
RoW
camrelizumab + famitinib, pembrolizumab, camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer
12/23
12/25
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
He, Lang
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
NCT06540521: Bolt CSP-M Holter Study

Recruiting
N/A
75
RoW
No intervention
Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Bradycardia
08/25
10/25

Download Options